Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Kelly

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Human Mutation|September 18, 2009
Defining the pathogenic role of telomerase mutations in myelodysplastic syndrome and acute myeloid leukemiaMichael Kirwan, Tom Vulliamy, Anna Marrone, et al.
American Journal of Hematology|February 13, 2024
Real-world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuriaMorag Griffin, Richard Kelly, Isabelle Brindel, et al.
BJU International|October 8, 2021
Real-world use of first-generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration-resistant prostate cancerRichard Kelly, Angelyn Anton, Shirley Wong, et al.
European Journal of Haematology|June 1, 2021
The incidence and prevalence of patients with paroxysmal nocturnal haemoglobinuria and aplastic anaemia PNH syndrome: A retrospective analysis of the UK's population-based haematological malignancy research network 2004-2018Stephen J Richards, Daniel Painter, Anita J Dickinson, et al.
BJU International|November 13, 2022
Prostate-specific membrane antigen positron emission tomography-computed tomography use prior to systemic therapy in metastatic castration-resistant prostate cancerRichard Kelly, Andrew Jensen, Nathasha Karunaratna, et al.
Blood Advances|December 18, 2024
Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and is associated with high response ratesAna Rita da Fonseca, Caio Cesar Justino, Vinicius Campos de Molla, et al.
British Journal of Haematology|February 16, 2010
The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumabRichard Kelly, Louise Arnold, Stephen Richards, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2024
Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 TrialNigel H Russell, Abin Thomas, Robert K Hills, et al.
Blood Advances|September 8, 2022
Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentationHarry J Iland, Nigel Russell, Richard Dillon, et al.
The Lancet. Haematology|March 31, 2022
Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trialDavid I Marks, Amy A Kirkwood, Clare J Rowntree, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Human Mutation|September 18, 2009
Defining the pathogenic role of telomerase mutations in myelodysplastic syndrome and acute myeloid leukemiaMichael Kirwan, Tom Vulliamy, Anna Marrone, et al.
American Journal of Hematology|February 13, 2024
Real-world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuriaMorag Griffin, Richard Kelly, Isabelle Brindel, et al.
BJU International|October 8, 2021
Real-world use of first-generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration-resistant prostate cancerRichard Kelly, Angelyn Anton, Shirley Wong, et al.
European Journal of Haematology|June 1, 2021
The incidence and prevalence of patients with paroxysmal nocturnal haemoglobinuria and aplastic anaemia PNH syndrome: A retrospective analysis of the UK's population-based haematological malignancy research network 2004-2018Stephen J Richards, Daniel Painter, Anita J Dickinson, et al.
BJU International|November 13, 2022
Prostate-specific membrane antigen positron emission tomography-computed tomography use prior to systemic therapy in metastatic castration-resistant prostate cancerRichard Kelly, Andrew Jensen, Nathasha Karunaratna, et al.
Blood Advances|December 18, 2024
Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and is associated with high response ratesAna Rita da Fonseca, Caio Cesar Justino, Vinicius Campos de Molla, et al.
British Journal of Haematology|February 16, 2010
The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumabRichard Kelly, Louise Arnold, Stephen Richards, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2024
Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 TrialNigel H Russell, Abin Thomas, Robert K Hills, et al.
Blood Advances|September 8, 2022
Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentationHarry J Iland, Nigel Russell, Richard Dillon, et al.
The Lancet. Haematology|March 31, 2022
Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trialDavid I Marks, Amy A Kirkwood, Clare J Rowntree, et al.
Pageof 7